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Summary We studied the effects of5-ethynyluracil (GW776), a potent inactivator ofdihydropyrimidine dehydrogenase, on the metabolism of
5-fluorouracil (5-FU), in particular with respect to formation of the toxic compounds fluoroacetate (FAC) and 2-fluoro-3-hydroxypropionic acid
(FHPA), using fluorine-19 nuclear magnetic resonance and the isolated perfused rat liver model. Livers were perfused with 5-FU alone at a
dose of 15 mg kg-' body weight orwith 5-FU + GW776 at doses of 15 mg 5-FU kg-' bodyweight and 0.5 mg GW776 kg-' bodyweight injected
1 h before 5-FU. All 5-FU was metabolized in experiments with 5-FU alone whereas unmetabolized 5-FU represented 94% of the fluorinated
compounds measured in experiments with 5-FU + GW776. GW776 modulated both the catabolic and the anabolic pathways of 5-FU, the
most striking effect being on the degradative pathway. The amount of 5-FU catabolites decreased by a factorof 27 in the presence of GW776.
The modulator led to a decrease in a-fluoro-3-alanine (FBAL) formation by a factor of approximately 110, while fluoride ion formation
decreased by a factor of approximately 10. By strongly lowering the metabolism of 5-FU into FBAL, GW776 circumvented the transformation
of FBAL into toxic FAC and FHPA. 5-FU anabolites increased by a factor of approximately 7 in the presence of GW776. The level of free
fluoronucleotides and 5-fluorouridine-5'-diphosphate sugars was increased up to fivefold. No incorporation of 5-FU into RNA could be
measured in experiments with 5-FU alone whereas, although low (0.1% of 5-FU injected dose), it was detectable in experiments with
5-FU + GW776. These results suggest that GW776 may be useful for attenuating the not very common but serious cardiotoxic and/or
neurotoxic side-effects of 5-FU that are probably due to FBAL metabolites.
Keywords: 5-fluorouracil; 5-ethynyluracil (GW776); 19F nuclear magnetic resonance; modulation of 5-fluorouracil metabolism; fluoroacetate;
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5-Fluorouracil (5-FU) is one of the most commonly used anti-
cancer agents for treatment of solid tumours. Common clinical
adverse reactions include myelosuppression, diarrhoea, vomiting
and mucositis. Over the last decade, the number of reports of
cardiotoxicity and neurotoxicity attributed to 5-FU has rapidly
increased (Anand, 1994; Yeh and Cheng, 1994; and references
cited therein). The biochemical mechanism underlying these toxic
side-effects remains unclear, although it has been postulated that
5-FU, and more precisely its main catabolite ex-fluoro-p-alanine
(FBAL) (Mukherjee and Heidelberger, 1960; Bemadou et al,
1985; Heggie et al, 1987; Hull et al, 1988), might be transformed
into fluoroacetate (FAC) (Koenig and Patel, 1970), a highly
cardiotoxic and neurotoxic poison (Pattison and Peters, 1966). We
demonstrated on the isolated perfused rabbit heart model that
commercial solutions of 5-FU contain cardiotoxic impurities,
namely fluoromalonic acid semialdehyde (FMASAld) and fluoro-
acetaldehyde (Facet), that are derived from the degradation of
5-FU in the basic medium required for its solubilization and are
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metabolized into FAC and 2-fluoro-3-hydroxypropionic acid
(FHPA), another cardiotoxic compound (Lemaire et al, 1992,
1994). Moreover, we were the first to demonstrate experimentally
the biotransformation ofpure 5-FU into two new catabolites, FAC
and FHPA, in the isolated perfused rat liver (IPRL) model and in
rats (Arellano et al, 1994). This demonstration was extended to the
bioconversion of 5-FU into FHPA in humans (Lemaire et al,
1996). 5-FU metabolism thus progresses further than FBAL,
giving rise to two toxic compounds. We therefore proposed that
the cardiotoxicity of5-FU could stem from two sources: (1) degra-
dation products of 5-FU formed over time in basic medium and
(2) metabolism of5-FU itself.
5-Ethynyluracil (GW776) is a potent inactivatorofthe catabolic
pathway of 5-FU acting on dihydropyrimidine dehydrogenase
(DPD), the enzyme that converts 5-FU into its first catabolite,
5,6-dihydro-5-fluorouracil (FUH2), thereby preserving 5-FU from
its rapid and extensive catabolism (Porter et al, 1992; Baccanari et
al, 1993; Spectoret al, 1993). Increases in the 5-FU half-life and in
the renal elimination ofunchanged 5-FU were recently reported in
cancer patients (Khor et al, 1996). GW776 greatly improved the
anti-tumour efficacy, the oral bioavailability and the therapeutic
index of 5-FU in animals (Baccanari et al, 1993; Cao et al, 1994).
Moreover, Davis et al (1994) demonstrated that GW776 protected
dogs from 5-FU-induced neurotoxicity that could be due to FAC
(Koenig and Patel, 1970; Okeda et al, 1984, 1990).
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Table 1 LDH activity and bile flow in control liver experiments and liver experiments with 5-FU alone and with 5-FU + GW776
t(min)
30 60 90 120 150 180 210 240
LDH±s.d. 11±4 11±5 19±20 26±27 41±27 56±40 66±52 69±28
(mUl min-1 g-1)
in control
LDH±s.d. 11±6 9±4 14±3 9±2 16±5 35±9 59±25 82±29
(mUl min-' g-1)
in 5-FU alone
LDH±s.d. 15±3 8±0 14±11 25±10 46±6 58±12 62±13 68±11
(mUl min-' -g1)
in 5-FU + GW776
Bile flow ±s.d. 1.27 ± 0.49 1.05± 0.41 0.90± 0.34 0.76± 0.28 0.48± 0.25 0.21 ± 0.15 0.12± 0.14 0.09± 0.13
(mg min-' g-1)
in control
Bile flow ± s.d. 1.38 ± 0.14 1.10 ± 0.31 1.00 ± 0.18 0.68 ± 0.12 0.35 ± 0.10 0.17 ± 0.05 0.09 ± 0.05 0.08±0.04
(mg min-' g-1)
in 5-FU alone
Bile flow ± s.d. 1.09 ± 0.08 0.88 ± 0.22 0.78 ± 0.09 0.56 ± 0.04 0.30 ± 0.04 0.13 ± 0.01 0.11 ± 0.01 0.08 ± 0.03
(mg min-' g-1)
in 5-FU + GW776
The purpose of the present study was thus to test the effects of
GW776 on 5-FU metabolism, in particular with respect to forma-
tion of the toxic compounds FAC and FHPA, using fluorine-19
nuclear magnetic resonance ('9F-NMR) and the IPRL model.
MATERIALS AND METHODS
IPRL experiments
Livers from male Wistar rats (Iffa Credo, Lyon, France) were
isolated and perfused with recirculation of the perfusion medium
according to the design originally described by Brauer et al (1951)
and modified by Sabouraud et al (1993). The recirculating
perfusate (approximately 180 ml), oxygenated with oxygen-
carbon dioxide (95%:5%), was a Krebs-Ringer bicarbonate buffer
supplemented with glucose (1.3 mM) and bovine serum albumin
(0.5%). The perfusate (pH 7.4) was recirculated at a mean flow rate
of 10 ml min-1 g-' of liver. The experiments were carried out with
solutions of5-FU prepared immediately before use at a dose of 15
mg kg-' body weight. For experiments with 5-FU alone, the drug
was injected into the perfusate after 1 h of liver equilibration, and
the experiments (n = 5) were continued for 3 h. For experiments
with 5-FU + GW776, 5-FU was injected after 1 h ofliverequilibra-
tion in thepresence ofGW776 atadose of0.5 mgkg-' body weight
(Spector et al, 1993), and the experiments (n = 4) were continued
for 3 h. A 0.5 M sodium bicarbonate solution was continuously
infused into the reservoir to maintain the pH ofthe perfusate at 7.4.
The temperature and pH of the perfusate, portal vein pressure and
bile flow were continuously monitored. Bile was collected in
preweighed vials at 30-min intervals after the beginning ofthe liver
perfusion. Liver viability was assessed by measuring lactate dehy-
drogenase (LDH) activity in the perfusate every 30 min.
The pH, vascularresistance, oxygen consumption, LDH activity
and bile flow were in the range of the literature values (Sugano et
al, 1978; Van Dyke et al, 1983). The evolution ofLDH activity and
bile flow are shown in Table 1. There was no significant difference
in values of LDH activity in control experiments and in experi-
ments with 5-FU alone and with 5-FU + GW776. The bile flow
was slightly weaker in experiments with 5-FU + GW776 than in
control experiments and in experiments with 5-FU alone, but it
was in the range of other experiments with 5-FU that are not
reported here.
At the end of the experiments, an aliquot of the perfusate was
immediately frozen and kept at - 80°C until '9F-NMR analysis.
The remaining perfusate was freeze-dried and then resuspended in
-3 ml of water immediately before 19F-NMR analysis. Bile
samples were gathered and stored at - 80°C until analysis. Liver
was weighed, immersed in liquid nitrogen, powdered and sequen-
tially extracted with cold and hot 1 M perchloric acid by using the
method of Wain and Staatz (1973). The acid-soluble and acid-
insoluble fractions thus obtained were lyophilized to dryness and
stored at - 80°C until analysis. The lyophilized materials were
then resuspended in approximately 2.5 ml of water containing
30 mM EDTA immediately before 19F-NMR analysis.
Verification of the metabolic origin of FAC and FHPA
To check that the formation of FAC and FHPA was a metabolic
process rather than a chemical transformation of 5-FU or FBAL
taking place during the perfusion, several control experiments
were carried out.
We first checked the purity ofthe solution of5-FU injected and
demonstrated that it was not chemically transformed in the
perfusate bubbled with carbogen for 3 h at 37°C. Indeed, the 19F-
NMR spectrum of the perfusion medium after concentration by
freeze-drying displayed the single 5-FU peak. We also carried out
fourcontrol experiments in which the perfusate containing 5-FU at
a concentration of45 mg kg-' body weight (calculated for a mean
rat body weight of 400 g) was circulated for 3 h in the perfusion
system without liver. The '9F-NMR spectra of these perfusates
after concentration only exhibited a strong peak corresponding to
BritishJournal ofCancer (1997) 76(9), 1170-1180 0CancerResearch Campaign 19971172 MArellano etal
5-FU, which made up 99.8 ± 0.07% of all the fluorinated
compounds detected, the fluoride ion (F-) signal representing
0.05 ± 0.02% and two very weak signals at 6 = - 111.3 and
-111.6 p.p.m. (0.08 ± 0.05% and 0.03 ± 0.01% respectively) not
corresponding to any of the signals observed in the concentrated
perfusates from the IPRL experiments with 5-FU.
Two control experiments were carried out with FBAL. We first
recorded the '9F-NMR spectrum of a solution of FBAL in the
perfusion medium over a period of 3 h and only detected the
signals of FBAL (98.9%) and N-carboxy-a-fluoro-,-alanine
(CFBAL; 1.1%). We also carried out one control experiment
in which the perfusate containing FBAL at a concentration of
16.6 mg kg-' body weight (dose equivalent to 15 mg 5-FU kg-'
body weight and calculated for a mean rat body weight of 400 g)
was circulated for 3 h in the perfusion system without liver. The
'9F-NMR spectrum of this perfusate after concentration only
displayed the signals of FBAL, which made up 18.3% of all the
fluorinated compounds detected, CFBAL representing 49.6%,
F- 1.4% and the adducts of FBAL with a-glucose 2.4% and
,-glucose 28.3%.
NMR spectroscopy
19F-NMR spectra were recorded at 282.4 MHz with 'H-decoupling
on a Bruker WB-AM 300 spectrometer in the following condi-
tions: probe temperature, 25°C; sweep width, 41 667 Hz; 32 768
data points zero-filled to 65 536; pulse width, 7 js (flip angle
approximately 400 in non-concentrated perfusate and bile, approx-
imately 300 in perchloric acid extracts and approximately 200 in
concentrated perfusate); pulse interval, 1.4 s for quantification of
concentrated perfusates, acid-soluble and acid-insoluble extracts
or 3.4 s for quantification of non-concentrated perfusates and bile
samples; number ofscans, 10 000-50 000; line broadening caused
by exponential multiplication, 6 Hz. The chemical shifts (6) were
reported relative to the resonance peak oftrifluoroacetic acid (5%
w/v aqueous solution) used as external chemical shift reference.
The concentrations of the fluorinated compounds were measured
by comparing the expanded areas of their NMR signals with that
of the external standard for quantification placed in a coaxial
capillary, namely a solution of sodium parafluorobenzoate
(FBEN) in deuterium oxide doped at saturation with
chromium(III) acetylacetonate (Cr(acac)3) to shorten the longitu-
dinal relaxation time (T,) ofFBEN. The apparent concentration of
the FBEN peak was previously calibrated. Cr(acac)3 (approxi-
mately 2.5 mg) was also added to non-concentrated perfusates and
bile samples. The areas were determined after the different signals
were cut out and weighed.
Fully relaxed spectra were obtained for all media analysed, even
when spectra were recorded with a pulse interval as short as 1.4 s
and without Cr(acac)3. This was demonstrated for (1) 5-FU, FAC
and FHPA in concentrated perfusates recorded with a pulse
interval of 1.4 s or 3.4 s without Cr(acac)3 or 10.4 s with Cr(acac)3,
(2) 5-FU and FBAL in acid-soluble extracts containing EDTA
recorded with a pulse interval of 1.4 s without Cr(acac)3 or 3.4 s
with Cr(acac)3. The differences between the values of concentra-
tions thus determined were not more than 10%, which corresponds
to the precision of the method (5-10% depending on the concen-
tration; Malet-Martino and Martino, 1992). The high ionic
strength of concentrated perfusates and perchloric acid extracts
and the high viscosity ofthe formermedium induced a decrease of
the flip angle for a given value ofthe pulse width (see above) and
probably ofthe T1, leading to an accurate quantification even with
a low pulse interval and without Cr(acac)3.
As a step of lyophilization was necessary to measure FHPA
and FAC concentrations, we checked the recovery of these two
compounds from the lyophilization pellet. Known amounts of
FHPA and FAC were added to 450 ml ofblank perfusate atconcen-
trations close to those found in the perfusates from rat liver experi-
ments. Three 150-ml fractions were freeze-dried and taken up in
water under our normal operating conditions. '9F-NMR spec-
troscopy showed that only 76 ± 2% and 63 ± 15% of FHPA and
FAC, respectively, were recovered. The amounts ofFHPA and FAC
measured in our experiments were thus underestimated as material
remained in the pellet, which was not completely redissolved.
We noticed that the amounts of FBAL (and derivatives) and
F- measured in concentrated perfusates were lower than in non-
concentrated perfusates. Of FBAL (and its derivatives), 71 ± 9%
was recovered in concentrated perfusates of experiments with
5-FU alone, whereas only 46± 10% ofF- was recovered in exper-
iments with 5-FU alone and with 5-FU + GW776. This led us to
quantify all the 5-FU metabolites in non-concentrated perfusates,
except when they were not detected (FBAL and related
compounds in 5-FU + GW776 experiments and FAC and FHPA in
5-FU experiments).
Statistical analysis
All results were expressed as means ± s.d. When necessary, statis-
tical significance was determined using Student's t-test. A P-value
of< 0.05 was considered to be statistically significant.
RESULTS
Qualitative analysis
IPRL were treated with pure 5-FU at a 'therapeutic' dose of 15 mg
kg-' body weight for 3 h with (n = 4) or without (n = 5) a 1-h prior
treatment with GW776 at a dose of 0.5 mg kg-' body weight
(Spector et al, 1993).
A characteristic '9F-NMR spectrum of a non-concentrated
perfusate from an IPRL treated with 5-FU alone shows the large
signals of 5-FU main catabolites, FBAL at 6 = -112.4 p.p.m. and
F- coming from the defluorination of FBAL (Martino et al, 1985;
Porter et al, 1995) at 6 = - 43.5 p.p.m. Low signals from a-fluoro-
,B-ureidopropionic acid (FUPA) at 6 = - 110.7 p.p.m. and CFBAL
derived from the interaction of bicarbonate ion with FBAL
(Martino et al, 1987) at 6 = - 110.9 p.p.m. could also be detected
(Figure IA). A large signal of 5-FU at 6 = - 93.3 p.p.m. and a
weak resonance for F- were observed in the '9F-NMR spectrum
of a non-concentrated perfusate from an IPRL treated with
5-FU + GW776 (Figure iB). FUH2 was not observed in any ofthe
experiments.
A characteristic '9F-NMR spectrum of a concentrated perfusate
from an IPRL treated with 5-FU alone (Figure 2A) shows the
signals ofFBAL at 6= - 112.6 p.p.m., CFBAL at 6=- 111.4 p.p.m.
and F- at 6 = - 49.0 p.p.m. The differences in the values of
chemical shifts in non-concentrated and concentrated perfusates
are mainly due to the much higher ionic strength in the concen-
trated perfusates and to differences in pH (7.6 vs 8.3 respectively).
More CFBAL was present in the concentrated perfusates (compare
Figures IA and 2A) as the proportion of CFBAL with respect to
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Figure 1 19F-NMR spectra of a non-concentrated perfusate from an isolated perfused rat liver treated (A) with 5-FU-alone (15 mg kg-1 body weight) or (B) with
5-FU + GW776 (15 mg 5-FU kg-' body weight and 0.5 mg GW776 kg-' body weight injected 1 h before 5-FU). (A) pH 7.4. (B) pH 7.5
FBAL increases with pH up to about pH 9 (Martino et al, 1987).
The strong resonance at 6 = - 111.0 p.p.m. and the weak signal at
6= - 110.4 p.p.m. are artifacts offreeze-drying. These two signals
only appear in the concentrated perfusates and correspond to
adducts of metabolic FBAL in the R configuration (Duschinsky
et al, 1973; Gani et al, 1985) with 5-glucose (FBAL[R]-
gluc,B, 6 = - 111.0 p.p.m.) and a-glucose (FBAL[R]-gluca,
6 = - 110.4 p.p.m.). The two signals at 6 = - 113.6 p.p.m. and
- 141.3 p.p.m. were assigned to FHPA and FAC, respectively, and
were positively identified by spiking a perfusate with authentic
standards. The control experiments described in Materials and
methods showed unambiguously that FAC and FHPA did not arise
from a chemical transformation of 5-FU or FBAL taking place
during the perfusion experiment orthe freeze-drying step but were
formed via a metabolic process. In a '9F-NMR spectrum of a
concentrated perfusate from an IPRL treated with 5-FU + GW776
(Figure 2B), a large signal of 5-FU at 6 = - 93.2 p.p.m. and low
signals from FBAL[R]-gluc,, CFBAL, FBAL, F- and 5-fluorouri-
dine (FUR) at 6 = - 88.0 p.p.m. were observed.
In bile samples from experiments with 5-FU alone (Figure
3A), the resonances of FBAL (6 = - 112.4p.p.m.) and F- (6 =
- 43.5 p.p.m.) were observed together with those of FBAL
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Fligure 2 19F-NMR spectra of aconcentrated perfusate from an isolated perfused rat liver treated (A) with 5-EU alone (15 mgkg-1 body weight) or (B) with
5-EU + GW776 (15 mg 5-EU kg-1 body weight and 0.5mg GW776 kg-1 body weight injected 1 h before 5-EU). (A) pH 8.3. (B) pH 8.4
conjugates with bile acids, most probably the conjugates
with cholic, deoxycholic and muricholic acids (6 = 110.3,
110.7 p.p.m. and 110.9 p.p.m., the last signal being low and
observed in only two out of five experiments) (Malet-Martino et
al, 1988; Sweeny et al, 1988). A characteristic 19F-NMR spectrum
of a bile sample from an experiment with 5-FU + GW776 only
exhibited the signal of F- (Figure 3B).
In the acid-soluble extract of liver treated with 5-FU alone, the
major signal corresponded to FBAL (6 = 112.3 p.p.m.). The
other resonances were those of fluoronucleotides (FNUCts;
= 89.2 p.p.m.), 5-fluorouridine-5'-diphosphate sugars (FUDP
sugars;
= 89.1 p.p.m.) and unknown compounds (6
= 93.8,
110.1, 110.4 and 110.8 p.p.m.), which probably arose from
chemical degradation of FBAL occurring during the step in very
acidic medium necessary to extract the liver (Figure 4A). The
main signal found in the acid-soluble extract of liver treated with
5-FU + GW776 was that of 5-FU (6 = 93.4 p.p.m.). FNUCts
and FUDP sugars led to four well-resolved resonances at =
89.04, 89.07, 89.16 and 89.27 p.p.m. Other signals were
those of FUR (6 = 90.0 p.p.m.), FBAL and the unknown
compound resonating at = 93.8 p.p.m. (Figure 4B).
The signal of FBAL (6 = 112.3 p.p.m.) was the only one
detected in the acid-insoluble extract of liver treated with 5-FU
alone (Figure 5A). It probably came from the incomplete extrac-
tion of the acid-soluble fraction. On the other hand, the '9F-NMR
spectrum of an acid-insoluble extract of a liver treated with
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Figure 3 19F-NMR spectra of a bile sample from an isolated perfused rat liver treated (A) with 5-FU alone (15 mg kg-1 body weight) or (B) with 5-FU + GW776
(15 mg 5-FU kg-' body weight and 0.5 mg GW776 kg-' body weight injected 1 h before 5-FU). (A and B) pH 8.5.
5-FU + GW776 showed the signals of5-fluorouridine-2'-monophos-
phate (2'-FUMP; 5 = - 89.5 p.p.m.) and 5-fluorouridine-3'-mono-
phosphate (3'-FUMP; 8 = -89.8 p.p.m.), which arose fromthe acidic
hydrolysis at 70°C of 5-FU incorporated into RNA (Parisot et al,
1991). Alow signalof5-fluorouridine-5'-monophosphate (5'-FUMP;
S = -89.2 p.p.m.) and theresonance of5-FU(S = -93.4p.p.m.) were
also observed (Figure SB). These compounds probably came from
theincomplete extraction ofthe acid-soluble fraction.
Quantitative analysis
Global recovery of5-FUandits metabolites
The data are presented in Table 2. The global recovery is identical
(approximately 67%) in the two sets ofexperiments. We checked the
error of the '9F-NMR assay by adding a known amount of5-FU to
150 ml of blank perfusate (final concentration 9.5 x 104 M) and by
dosing three separate aliquots. '9F-NMR spectroscopy showed that
95.0± 0.7% of5-FU was recovered. The 19F-NMR assay is therefore
accurate and the error made on it cannot explain the missing amount
ofdrugand/ormetabolites inliverexperiments. We noticedthatthere
was anevaporation ofperfusateduring the4hofperfusion. To quan-
tify this loss, we carried out 12 control experiments as follows. The
perfusate containing 5-FU at a concentration of 15 or 45 mg kg-'
body weight (calculated for a mean rat body weight of 400 g), or
FBAL or 5'-deoxy-5-fluorouridine at a concentration equivalent to
15 or 45 mg 5-FU kg-' body weight, respectively, was circulated for
3 h in the perfusion system without liver. The mean volume of
perfusate lost during these experiments was 38.9 ± 5.6 ml. This loss
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Figure 4 19F-NMR spectra of an acid-soluble extract from an isolated perfused rat liver treated (A) with 5-FU alone (15 mg kg-lbody weight) or (B) with
5-FU + GW776 (15 mg 5-FU kg-1 body weight and 0.5 mg GW776 kg-' body weight injected 1 h before 5-FU). (A and B) pH 5.4
was due to the temperature in the perfusion device, the high speed
of perfusate recirculation and the high flow rate of carbogen
bubbling, both necessary to insure a correct oxygenation of the
liver. The meanrecovery offluorinatedcompound was 85.6 ± 3.1%,
clearly demonstrating that approximately 15% of the injected dose
of 5-FU, FBAL or 5'-deoxy-5-fluorouridine was evaporated with
the perfusate during the liver perfusion. The remaining missing
drug and/or metabolites (approximately 19%) probably stayed in
the liver that was not completely extracted with the extraction
methodology used in our study.
All 5-FU was metabolized in experiments with 5-FU alone,
whereas 64% of the injected 5-FU (i.e. approximately 94% of the
fluorinated compounds measured) was recovered unchanged in
experiments with 5-FU + GW776. The amount of5-FU catabolites
decreased by a factor of 27 in the presence of GW776, whereas
5-FU anabolites increased by a factor of7.
Proportions of5-FU and its metabolites
The data are presented in Table 3. In the experiments with 5-FU
alone, FBAL was the main catabolite as it represented 44% of the
5-FU-injected dose whereas F-, present in trace amounts, was the
main catabolite (2% of injected dose) in the experiments with
5-FU + GW776.
The main characteristics of the experiments with 5-FU +
GW776 are (1) the decrease in FBAL formation by a factor of
-110, (2) the absence ofFAC and FHPA formation [although only
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Fligure 5 '9F-NMR spectra of anacid-insoluble extract from an isolated perfused rat liver treated (A) with 5-FU alone (15 mg kg-1 body weight) or (B) with
5-EU + GW776 (15mg 5-EU kg-1 body weight and 0.5 mg GW776 kg-' body weight injected 1 h before 5-EU). (A and B) pH 5.4
small amounts of FHPA and FAG were found in the perfusates of
experiments with 5-FU alone (FHPA represented 0.4% and FAC
0.1I% of the injected 5-EU)] and (3) the increase by a factor of
approximately 5 of FNUCts and FUDP sugars and the low but
measurable incorporation of5-EU into RNA.
Repartition of5-FU and metaboites in the different media
analysed (perfusate, bile andliver)
The data presented in Table 4 indicate that, for all experiments,
most of the fluorinated compounds were found in the perfusate.
Almost identical amounts of fluorinated compounds were
measured in bile samples and acid-insoluble extracts. On the other
hand, the proportion of fluorinated compounds is much higher in
acid-soluble extracts from experiments with 5-EU alone (13%)
than from experiments with 5-EU + GW776 (=3%).
FBAL and F were the main compounds in perfusates from
experiments with 5-EU alone (making up, respectively, approxi-
mately 58% and approximately 40% ofthe fluorinated compounds
measured inperfusates), whereas unmetabolized 5-EU represented
approximately 97% in perfusates from experiments with 5-EU +
GW776. Only 5-EU catabolites were found in bile samples, essen-
tially FBAL and FBAL conjugates in 5-EU-alone experiments and
only F in 5-EU + GW776 experiments. Although the catabolic
pathway was reduced by a factor of 27 when 5-EU was injected in
association with GW776, the trace amount of F was about five-
foldhigher in bile samples from experiments with 5-EU + GW776.
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Table 2 Global recovery of 5-FU and metabolites in experiments with 5-FU alone and with 5-FU + GW776
Compounds Per cent of injected dose ± s.d.
Experiments with 5-FU alone Experiments with 5-FU + GW776
Unmetabolized 5-FU 0 64 ± 3
Catabolites 66 ± 5 2.4 ± 0.8
Anabolites 0.16 ± 0.04a 1.1 ± 0.3a
Total 66 ± 5b 68 ± 4b
a Significant at P< 0.0005. bNot significant (P> 0.1).
Table 3 Proportions of 5-FU and metabolites in experiments with 5-FU alone and with 5-FU + GW776
Compounds Percent of injected dose ± s.d.
Experiments with 5-FU alone Experiments with 5-FU + GW776
Unmetabolized 5-FU 0 64 ± 3
Catabolites
FUPA 0.6 ± 0.7 0
FBAL 44 ±lla 0.4± 0.2b
F- 22±7 2±1
FACc 0.11±0.04 0
FHPAc,d 0.42 ± 0.06 0
Anabolites
5' FNUCt and FUDP sugars 0.16 ± 0.04e 0.8 ± 0.4e
FU-RNA (2' and 3' FUMP) 0 0.09 ± 0.01
FUR Of 0.3±0.1
aFBAL includes FBAL and CFBAL in non-concentrated perfusate, FBAL and FBAL conjugates with bile
acids in bile, FBAL and unknown compounds ( = - 93.8, - 110.1, - 110.4 and - 110.8 p.p.m.) in acid-
soluble extract and FBAL in acid-insoluble extract. bFBAL includes FBAL, CFBAL, FBAL[R]-gluc, in
concentrated perfusate, and FBAL and unknown compound (3 = - 93.8 p.p.m.) in acid-soluble extract.
cFAC and FHPA could only be assayed in concentrated perfusate. dThe signal of FHPA in non-
concentrated perfusate is in the base of the large signal of FBAL; it is thus already included when FBAL
signal is assayed. eSignificant at P< 0.01. 'Only observed in one experiment out of five, representing
0.02% of injected dose.
The amount of5-FU measured in acid-soluble extracts from exper-
iments with 5-FU + GW776 was low compared with that ofFBAL
in acid-soluble extracts from experiments with 5-FU alone,
demonstrating that 5-FU, contrary to FBAL, is not stored into
hepatocytes. No anabolites were detected in acid-insoluble
extracts from 5-FU-alone experiments, whereas the experiments
with 5-FU + GW776 demonstrated a low incorporation of 5-FU
into RNA ofhepatocytes.
DISCUSSION
GW776 modulates both the catabolic and anabolic pathways of5-
FU, the most striking effectbeing on the degradative pathway. The
amount of5-FU catabolites decreased by afactor of27 in the pres-
ence of GW776 (Table 2). Rat livers were thus > 96% inhibited
in their ability to catalyse 5-FU degradation. This result is in
complete agreement with the study of Baccanari et al (1993),
which reported the same extent of inhibition when DPD activity
was measured in liver extracts prepared 1 h or 6 h after rats were
treated with a single dose ofGW776 (2 mg kg-' p.o.).
GW776 led to adecrease in FBAL formation by afactorof-I10,
whereas F formation decreased by a factor of only -10 (Table 3).
L-alanine-glyoxylate aminotransferase II (AlaAT-II) purified from
rat liver catalysed the elimination of F from FBAL. The enzyme
was not inactivated significantly during dehalogenation of FBAL,
and 5-FU was not a substrate (Porter et al, 1995). To explain our
data, one might therefore evoke a slight defluorination ofthe large
amounts ofunmetabolized 5-FU remaining during the experiments
with 5-FU + GW776 catalysed by another enzyme.
FAC is a highly cardiotoxic and neurotoxic poison (Pattison and
Peters, 1966) known to accumulate in the organism (Meldrum and
Bignell 1957). We checked the cardiotoxicity of FHPA on the
isolated perfused rabbit heart model at two doses, 0.01 and
1.5 mg kg-'. FHPA did not generate cardiotoxic symptoms at the
lowest dose but was highly cardiotoxic on this model at the highest
dose (unpublished data). Moreover, FBAL, the precursor ofFHPA
and FAC (Arellano et al, 1994), accumulated in rats and was
retained up to 8 days in various tissues, mainly liver, heart and
brain (Zhang et al, 1992, 1993). By greatly lowering the metabo-
lization of5-FU into FBAL, GW776 circumvents the formation of
toxic FHPA and FAC (Table 3). The present results therefore
support the earlier report of Davis et al (1994). These authors
demonstrated that GW776 protected dogs from the neurotoxicity
induced by a 26-h continuous infusion of5-FU at three doses (1.6,
4 or 16 mg kg-' 24 h-') and suggested with others (Koenig and
Patel, 1970; Okeda et al, 1984, 1990) that 5-FU catabolites are
responsible for this dose-limiting toxicity in dogs and cats, which
are particularly sensitive.
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Table 4 Repartition of 5-FU and metabolites in perfusate, bile and liver (acid-soluble and acid-insoluble extracts)
from experiments with 5-FU alone and with 5-FU + GW776
Medium and compound Per cent of Injected dose ± s.d.
Experiments with 5-FU alone Experiments with 5-FU + GW776
Perfusate
5-FU 0 62+3
FUR 0 0.2±0.1a
FUPA 0.6 ± 0.7 0
FBAL 30 ± 9b 0.12 ± 0.07ac
F- 21±7 1.6±0.8
FACa 0.11±0.04 0
FHPAa 0.42 ±0.06 0
Total 52+ 5d,e 64± 4e
Bile
FBAL 0.13 ± 0.04 0
FBAL conjugates 0.3 ± 0.2 0
F- 0.07 ± 0.02' 0.4 ± 0.3f
Total 0.5 ± 0.29 0.4± 0.39
Acid-soluble extract
5-FU 0 2.3 ± 0.6
FUR Oh 0.03± 0.006
FNUCts 0.16 ± 0.04e 0.75 ± 0.4e
FBAL 12.5±5 0.2±0.1
Unknown compound(s) 0.45 ± 0.06i 0.09 ± 0.04i
Total 13+ 4e 3.4 1.1e
Acid-insoluble extract
5-FU 0 0.09 0.10
5', 2'and3'FUMP 0 0.10 0.03
FBAL 0.17 ± 0.08 0
Total 0.17± 0.08g 0.19± 0.12g
aFUR, FBAL, FAC and FHPA could only be assayed in concentrated perfusate. bFBAL includes FBAL and CFBAL.
CFBAL includes FBAL, CFBAL and FBAL[R]-gluco. dThe signal of FHPA in non-concentrated perfusate is in the base
of the large signal of FBAL; FHPA is thus assayed at the same time as FBAL. This explains why the total does not
include the value found for FHPA. eSignificant at P< 0.01. 'Significant at P< 0.025. sNot significant (P> 0.1). hOnly
observed in one experiment out of five, representing 0.02% of injected dose. iThe unknown compounds resonate at
8 = - 93.8, - 110.1, - 110.4 and - 110.8 p.p.m. iOnly the unknown compound resonating at 8 = -93.8 p.p.m. could
be detected.
Alsointeresting is the effect ofGW776 on the anabolicpathway
of5-FU that confers to thedrug its cytotoxicity. GW776 increases
thetherapeutic index of5-FU in mouse(Baccanari etal, 1993) and
rat (Cao et al, 1994) tumour models. As GW776 prevents the
catabolism of5-FU and thus improves systemic exposure to5-FU,
one might expect an increase in the amounts of5-FU anabolites to
explain the betterefficacy. The liver is not the best model to study
5-FU anabolism. Moreover, the comparison between our experi-
ments with 5-FU alone and with 5-FU + GW776 would have been
more convincing with a lower dose of 5-FU when injected in
combination with GW776. We used the present dose to be able
to detect low amounts of catabolites. Nevertheless, our results
demonstrate that5-FU anabolites increasedby afactorof-7 in the
presence of GW776 (Table 2). The level of free FNUCts and
FUDP sugars was increased up to - fivefold (Table 3). No 5-FU
incorporated into RNA was observed in the experiments with
5-FU alone whereas the incorporation of5-FU into RNA, detected
as 2'- and 3'FUMP, was low (0.1% of the injected dose) but
detectable in the experiments with 5-FU + GW776 (Table 3).
Davis et al (1995) reported that, compared with mice treated with
5-FU alone, GW776 enhanced the incorporation of 5-FJ into
RNA in MOPC-315 s.c. tumours ofmice.
In conclusion, our study clearly shows that GW776 prevents
formation of FBAL and its subsequent metabolism into the toxic
FHPA and FAC. GW776 may therefore be useful not only for
improving the efficacy of 5-FU (Spector et al, 1994) but also for
attenuating cardiotoxic and/or neurotoxic side-effects ofthis anti-
tumour agent that may be due to FBAL metabolites. Although
these side-effects are not very common, they are severe and may
be dose limiting. The combination ofGW776 and 5-FU has great
clinical potential. GW776 increases the half-life of 5-FU from
approximately 14 minto approximately 5 h in humans (Khor et al,
1996) and thereby enables oral dosing to replace the 5-day bolus
and the protracted continuous infusion schedules (Baccanari et al,
1993). Moreover, the dry powder of orally formulated 5-FU
presents the advantage ofbeing devoid ofcardiotoxic breakdown
products found in i.v. solutions (Lemaire et al, 1992). This combi-
nation iscurrently in intemationalphase II clinical trials forbreast,
pancreatic, colorectal and hepatocellular cancer.
ABBREVIATIONS
5-FU, 5-fluorouracil; FBAL, a-fluoro-p-alanine; FAC, fluoro-
acetate; FMASAId, fluoromalonic acid semi-aldehyde; Facet,
fluoroacetaldehyde; FHPA, a-fluoro-p3-hydroxypropionic acid;
IPRL, isolated perfused rat liver; GW776, 5-ethynyluracil; DPD,
dihydropyrimidine dehydrogenase; FUH2, 5,6-dihydro-5-fluo-
rouracil; '9F-NMR, fluorine-19 nuclearmagnetic resonance; LDH,
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lactate dehydrogenase; EDTA, ethylene diamine tetraacetic acid; F-,
fluoride ion; CFBAL,N-carboxy-a-fluoro-p-alanine; FBEN, sodium
parafluorobenzoate; Cr(acac)3, chromium(III) acetylacetonate;
FUPA, ox-fluoro-p-ureidopropionic acid; FBAL [R]-glucp, FBAL
[S]-glucp, FBAL [R]-gluca, FBAL [S]-gluca, adducts of FEBAL
with P-glucose and oc-glucose; FUR, 5-fluorouridine; FNUCts, fluo-
ronucleotides; FUDP sugars, 5-fluorouridine-5'-diphosphate sugars;
2'-FUMP, 5-fluorouridine-2'-monophosphate; 3'FUMP, 5-fluorouri-
dine-3'-monophosphate; 5'FUMP, 5-fluorouridine-5'-monophos-
phate; AlaAT-II, L-alanine-glyoxylate aminotransferase
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